OurPath, a pioneering healthtech firm, has successfully secured £500,000 in funding. This milestone comes less than a year post-launch.
The company aims to revolutionise diabetes prevention by encouraging lifestyle changes through innovative programmes.
The recent funding of £500,000 was sourced from esteemed investors, including American VC 500 Startups and Bethnal Green Ventures. These investments signal a strong vote of confidence in OurPath’s potential and its strategic approach to combatting diabetes through lifestyle modification programmes.
OurPath’s programme leverages advanced technology to aid those at risk of type 2 diabetes. The initiative includes live support and educational content tailored to individual needs.
It uniquely integrates activity trackers and wireless scales, providing a comprehensive tool for behaviour change.
The programme comes as a response to the alarming statistic that one in three UK residents has pre-diabetes.
Without intervention, 70% of these individuals will develop type 2 diabetes, posing a significant public health challenge.
The programme costs £149 and is designed to be accessible to a broad audience, providing tools and support to mitigate this risk.
OurPath is distinguished as the first behavioural change programme commissioned by the NHS, highlighting its credibility and potential impact.
This collaboration underscores the programme’s importance in the national healthcare strategy against diabetes.
Participants benefit from a structured six-week plan that monitors weight and activity levels, coupled with diet plans and daily interactive content.
This approach ensures that participants receive continuous support and motivation to achieve healthier lifestyles.
The inclusion of real-time feedback and progress tracking further enhances the programme’s effectiveness.
Founded by Mike Gibbs and Chris Edson, both esteemed academics, OurPath embodies scientific and engineering excellence.
Their vision drives the company’s mission to transform preventative healthcare for diabetes.
With this new capital, OurPath looks to expand its reach and further innovate its programme offerings.
OurPath’s recent funding marks a pivotal step in addressing diabetes through innovative solutions. With a robust programme and strategic partnerships, it is poised for significant impact. The company’s forward-thinking approach and collaboration with the NHS underscore its potential to redefine diabetes prevention.
